e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis
Greg J. Fox, Andrea Benedetti, Helen Cox, Won-Jung Koh, Piret Viiklepp, Shama Ahuja, Geoffrey Pasvol, Dick Menzies,on behalf of the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB
Source:
Eur Respir J 2017; 49(1): 1600993; DOI: 10.1183/13993003.00993-2016
Journal Issue:
January
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Greg J. Fox, Andrea Benedetti, Helen Cox, Won-Jung Koh, Piret Viiklepp, Shama Ahuja, Geoffrey Pasvol, Dick Menzies,on behalf of the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2017; 49(1): 1600993; DOI: 10.1183/13993003.00993-2016
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis
Source: Eur Respir J 2013; 42: 169-179
Year: 2013
Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012
Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses
Source: Eur Respir J, 50 (1) 1700061; 10.1183/13993003.00061-2017
Year: 2017
Getting the best possible evidence from observational studies of treatment of multidrug-resistant tuberculosis patients
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013
Bedaquiline in the treatment of multidrug-resistant tuberculosis: a subanalysis in Korean population
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019
Mycobacterium tuberculosis
transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis
Source: Eur Respir J, 50 (4) 1701044; 10.1183/13993003.01044-2017
Year: 2017
Multicentre randomised clinic study of new standard chemotherapy regimen for new cases patients of pulmonary tuberculosis executed in Russia regions with high level of multiple drug resistance (MDR)
Source: Annual Congress 2009 - Tuberculosis control
Year: 2009
Evaluation of efficacy and safety of linezolid for the treatment of drug-resistant tuberculosis: case series report of 12 patients
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009
M
ycobacterium abscessus
pulmonary disease: individual patient data meta-analysis
Source: Eur Respir J, 54 (1) 1801991; 10.1183/13993003.01991-2018
Year: 2019
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China
Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020
Year: 2021
Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation
Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB)
Year: 2006
Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline
Source: Eur Respir J , 49 (3) 1700146; DOI: 10.1183/13993003.00146-2017
Year: 2017
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience
Source: Eur Respir J 2016; 47: 333-336
Year: 2016
Multi-drug resistant tuberculosis: a retrospective analysis of cases over 10 years in a low incidence setting
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
A multicentric cohort analysis of culture conversion and reversion in multidrug resistant tuberculosis (MDRTB) patients
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013
Results of traditional and new regimens of MDR/XDR TB treatment: cohort analysis
Source: International Congress 2019 – Drug-resistant tuberculosis
Year: 2019
Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007
Pulmonary tuberculosis (TB) in the adult: comparative analysis of two different groups
Source: Eur Respir J 2002; 20: Suppl. 38, 362s
Year: 2002
Is multidrug-resistant TB more common in children? An analysis of surveillance data
Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview
Year: 2012
Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept